Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,737 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Synucleinopathy Clear all

Conditions: Genetic Predisposition, Paraganglioma, Pheochromocytoma, ALS, Parkinson Disease, Polyneuropathies, Frontotemporal Dementia, Alzheimer Disease, Cardiomyopathy Non-ischemic, Thoracic Aortic Aneurysm
Interventions: Behavioral nudge; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: EvergreenHealth; Other
Eligibility: 30 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Kirkland, Washington

Conditions: Parkinson Disease, Depression
Interventions: OnabotulinumtoxinA, Control; Biological
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 95 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Parkinson's Disease
Interventions: High intensity exercise and balance training, Usual care arm exercise; Other
Lead sponsor: University of Nevada, Las Vegas; Other
Eligibility: 45 Years to 85 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Parkinson's Disease
Interventions: Physical exercise intervention, Cognitive exercise intervention, Health education; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 89 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parkinson Disease, Sleep
Interventions: Meditation; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Parkinson's Disease
Interventions: Istradefylline (KW-6002); Drug
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Parkinson Disease
Interventions: DPA-714-PET/MRI, 5-year Follow-up DPA-714-PET/MRI, DPA-714 Metabolite Analysis; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 30 Years and older
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Parkinson's Disease
Interventions: ROTIGOTINE; Drug
Lead sponsor: Luye Pharma Group Ltd.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 3
States / cities: Long Beach, California • Hallandale, Florida • Atlanta, Georgia

Conditions: Parkinson Disease
Interventions: OMM treatment arm, Counseling; Procedure · Other
Lead sponsor: New York Institute of Technology; Other
Eligibility: 40 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Old Westbury, New York

Conditions: Parkinson's Disease (PD)
Interventions: ABBV-951, Placebo for Levodopa/Carbidopa (LD/CD), Levodopa/Carbidopa (LD/CD), Placebo for ABBV-951; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 70
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more

Conditions: Hallucinations, Psychoses, Parkinson's Disease
Interventions: ACP-103; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 0 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 13
States / cities: Fountain Valley, California • Sunnyvale, California • Danbury, Connecticut + 10 more

Conditions: Dementia With Lewy Bodies
Interventions: Neflamapimod, Placebo; Drug
Lead sponsor: EIP Pharma Inc; Industry
Eligibility: 55 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 29
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 26 more

Conditions: Parkinson's Disease
Interventions: Tyrosine, Placebo Comparator:Sugar Pill; Dietary Supplement · Other
Lead sponsor: New York Institute of Technology; Other
Eligibility: 50 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Old Westbury, New York

Conditions: Parkinson's Disease
Interventions: Novel DBS stimulation patterns; Device
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Lewy Body Dementia, Parkinson Disease Dementia, Dementia With Lewy Bodies, Lewy Body Disease
Interventions: Peer Mentor Support and Caregiver Education, Caregiver Education; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 622 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Parkinson Disease
Interventions: Lithium; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 45 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Williamsville, New York

Conditions: Idiopathic Parkinson's Disease
Interventions: CVT-301 Low Dose, CVT-301 High Dose, Placebo; Drug · Other
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 55
States / cities: Scottsdale, Arizona • Fresno, California • Fullerton, California + 47 more

Conditions: Parkinson Disease
Interventions: SpeechVive device, Telemedicine interaction, In person interaction; Device · Behavioral
Lead sponsor: SpeechVive, Inc; Industry
Eligibility: 30 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Lafayette, Indiana • West Lafayette, Indiana

Conditions: Parkinson Disease, Parkinsonism, Lewy Body Disease, Supranuclear Palsy, Progressive, Parkinsonism Vascular, Multiple System Atrophy, Corticobasal Degeneration, Alzheimer Disease, Frontotemporal Dementia, Primary Progressive Aphasia, Vascular Dementia
Interventions: Palliative Care; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 105 Years
Enrollment: 783 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: San Francisco, California • Aurora, Colorado

Conditions: Parkinson Disease
Interventions: Dynamic Standing Desk; Device
Lead sponsor: University of Michigan; Other
Eligibility: 50 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy(PSP)
Interventions: Tributyrin, Placebo; Drug
Lead sponsor: Prabesh Kanel; Other
Eligibility: 45 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Parkinson Disease
Interventions: Human Dopaminergic Progenitor Cells; Biological
Lead sponsor: iRegene Therapeutics Co., Ltd.; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Using the EHR to Advance Genomic Medicine Across a Diverse Health System

Investigating Central Mechanisms of Overactive Bladder in Adults With Parkinson's Disease

Trial of OnabotulinumtoxinA for Depression in Parkinson Disease

High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's Disease

Telemedicine Intervention in Patients With Chronic Pain in PD

Quantitation of Glymphatic Functioning in Sleep and Meditative States

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy

Incidence of Parkinson's Disease Among Veterans

Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease

Effect of Osteopathic Manipulative Medicine on Parkinson Disease

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug

RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease

Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease

PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia

Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.

Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

Development of Software to Provide the SpeechVive Device Via the Internet

More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease

A Pilot Study of In-lab Dynamic Standing in Parkinson's Disease

Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial

This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.